Apricus Biosciences to Present at the 2017 BIO Investor Forum
(Thomson Reuters ONE) -
SAN DIEGO, Oct. 10, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc.
(Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in
urology and rheumatology, today announced that Richard Pascoe, Chief Executive
Officer, will present at the 2017 BIO Investor Forum on Wednesday, October
18, 2017, at 9:00 a.m. Pacific Time. The conference will be held at The Westin
St. Francis Hotel in San Francisco, CA. Mr. Pascoe will provide an update on
the Company's strategy and plans surrounding Vitaros(TM).
A live audio webcast of the presentation can be accessed via the Investor
Relations' section of the Company's website at www.apricusbio.com. Please log
in approximately 5-10 minutes before the event to ensure a timely connection. A
replay of the webcast will be available for 30 days following the presentation.
About Apricus Biosciences, Inc.
Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing
innovative medicines in urology and rheumatology. Apricus has two product
candidates currently in development. Vitaros is a product candidate in the
United States for the treatment of erectile dysfunction, which is in-licensed
from Warner Chilcott Company, Inc., now a subsidiary of Allergan plc (Allergan).
RayVa is our product candidate in Phase 2 development for the treatment of the
circulatory disorder Raynaud's phenomenon, secondary to scleroderma, for which
we own worldwide rights.
For further information on Apricus, visit http://www.apricusbio.com.
Vitaros(TM) is Apricus' trademark in the United States, which is pending
registration and subject to the agreement with Allergan. Vitaros(®) is a
registered trademark of Ferring International Center S.A. in certain countries
outside of the United States. RayVa(TM) is Apricus' trademark, which is
registered in certain countries throughout the world and pending registration in
the United States.
CONTACT: Matthew Beck
mbeck(at)troutgroup.com
The Trout Group
(646) 378-2933
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Apricus Biosciences, Inc. via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 10.10.2017 - 13:00 Uhr
Sprache: Deutsch
News-ID 563097
Anzahl Zeichen: 2713
contact information:
Town:
SAN DIEGO
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 188 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Apricus Biosciences to Present at the 2017 BIO Investor Forum"
steht unter der journalistisch-redaktionellen Verantwortung von
Apricus Biosciences, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
